Abstract
BackgroundLivin/BIRC7 is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process. This case-control study was intended to investigate livin/BIRC7 gene expression in endometrial hyperplasia and carcinoma and its correlation to some oxidative stress markers in addition to its possible diagnostic performance. MethodsThis study included 90 participants [30 endometrial hyperplasia patients, 30 endometrial carcinoma patients, and 30 healthy controls]. Livin/BIRC7 gene expression was analyzed using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Serum catalase activity was assessed by enzyme-linked immunosorbent assay (ELISA) and malondialdehyde level was measured by the colorimetric method. ResultsLivin/BIRC7 gene expression was significantly (p < 0.001) higher in endometrial carcinoma from patients with endometrial hyperplasia when compared to controls. A positive correlation was found between livin/BIRC7 expression and serum catalase activity and malondialdehyde level in endometrial hyperplasia and carcinoma. The detection of livin/BIRC7 in endometrial carcinoma has excellent sensitivity and specificity. ConclusionsLivin/BIRC7 was overexpressed in endometrial carcinoma with excellent power to differentiate endometrial carcinoma from endometrial hyperplasia or healthy subjects, suggesting that it might be a useful molecular marker for endometrial carcinoma diagnosis.
Highlights
Livin/Baculoviral inhibitor of apoptosis protein (IAP) repeat-containing 7 (BIRC7) is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process
This study involved 90 women divided into three groups: group 1—30 women with endometrial hyperplasia with a mean age ± standard error (SE) was 49.73 ± 1.07 years; group 2—30 women with endometrial carcinoma with a mean age ± SE was 52.16 ± 1.08 years, and group III—30 healthy controls with a mean age ± SE was 51.83 ± 1.30 years
The mean weight was higher in patients with endometrial hyperplasia compared to endometrial carcinoma patients and controls (p < 0.001 and p = 0.02; respectively)
Summary
Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family which are implicated in development of cancer through the inhibition of apoptosis process. This case-control study was intended to investigate livin/BIRC7 gene expression in endometrial hyperplasia and carcinoma and its correlation to some oxidative stress markers in addition to its possible diagnostic performance. During carcinogenesis and as a central step for cancer development, malignant cells inactivate apoptosis. A great number of the cases are diagnosed at the early stage (I or II) and showed a better prognosis and the possibility of no recurrence after surgery and adjuvant radiotherapy. There is a great responsibility from researchers to seek new biomarkers, which can serve as predictors and/or diagnostics for endometrial carcinoma
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
